Skip to content


Harry Cassin
Publisher and Editor

Andy Spalding
Senior Editor

Jessica Tillipman
Senior Editor

Bill Steinman
Senior Editor

Richard L. Cassin
Editor at Large

Elizabeth K. Spahn
Editor Emeritus

Cody Worthington
Contributing Editor

Julie DiMauro
Contributing Editor

Thomas Fox
Contributing Editor

Marc Alain Bohn
Contributing Editor

Bill Waite
Contributing Editor

Shruti J. Shah
Contributing Editor

Russell A. Stamets
Contributing Editor

Richard Bistrong
Contributing Editor

Eric Carlson
Contributing Editor

Corruption risk in pharma and medical device markets

At the 17th Annual Pharmaceutical and Medical Device Compliance Congress last month in Washington DC, Paul Hastings Partner Gary Giampetruzzi and FCPA Blog Contributing Editor Richard Bistrong exchanged perspectives on pharma compliance risks.

Their panel was “Behind the Bribe: Multiple Real World Perspectives on How Foreign Bribery Occurs, Is Investigated, and Could Be Prevented.”

Here’s a 15-minute clip of the discussion.

Share this post



  1. At the risk of sounding naive, how about a "zero tolerance" policy directive from leadership, including the BOD?

  2. How about the billions that are paid in bribes by Amgen to medical service providers here in the US? Paul Hastings aides and abetts this activity as their counsel. As a whistleblower I helped recover $780 million for taxpayers while AMGEN and Paul Hastings threatened to take my wife's disability away. Currently in NY I have a case to recover $7 billion that Amgen in a hub and spoke conspiracy defrauded Medicare and Medicaid. AMGEN and Paul Hastings have done everything possible to cover up this horrific corruption.

Comments are closed for this article!